Breast Neoplasm

In a study 202 breast cancer patients undergoing tamoxifen treatment, a higher frequency of wildtype TP53 patients responded to treatment compared to those with mutations in TP53 (66% wild-type vs. 31… (full text at CIViC)

PMID 10786679 · Berns et al., 2000 · Open in CIViC

Large meta-analysis of 5,191 breast cancer patients and 3,834 controls did not find a conclusive link between codon 72 allele and breast cancer susceptibility. Odds ratios were 0.98 (95% CI, 0.91–1.05… (full text at CIViC)

PMID 17909070 · Schmidt et al., 2007 · Open in CIViC

TP53 Y220C is known to destabilize p53 and down-regulate p53-mediated apoptosis. The success of bortezomib may be explained by the previously reported up-regulation of caspase-mediated apoptosis, whic… (full text at CIViC)

PMID 28679691 · Meißner et al., 2017 · Open in CIViC

High expression of betaIII-tubulin, as assessed in 85 breast cancers by IHC, was associated with better pathological response.

PMID 23218766 · Wang et al., 2013 · Open in CIViC

84 breast cancer samples acquired from commercial sources were assayed on Affymetrix human exon 1.0 arrays. A computational method was used to find potential gene fusions which assessed differential e… (full text at CIViC)

PMID 19737969 · Lin et al., 2009 · Open in CIViC

A meta analysis and systematic review of three trials with a total of 3748 breast cancer patients was undertaken to determine if VEGF-A plasma levels affected patient outcomes in response to bevacizum… (full text at CIViC)

PMID 25947646 · Santos et al., 2015 · Open in CIViC

Patients with high VEGF121and VEGF110 levels treated with bevacizumab compared to placebo show a trend toward improved PFS (HR 0.64, 95% CI, 0.47 to 0.88). The trend was not significant for patients w… (full text at CIViC)

PMID 27817944 · Miles et al., 2017 · Open in CIViC

Patients with high VEGF121and VEGF110 levels treated with bevacizumab and chemotherapy compared to chemotherapy only show a trend toward improved PFS. However this trend is not significant (HR 0.64; 9… (full text at CIViC)

PMID 23932548 · Cameron et al., 2013 · Open in CIViC

In VEGF-Axxxa high cases, the median OS of patients treated with taxane only (cohort A) was 26 months while the median OS of patients treated with paclitaxel/bevacizumab (cohort B) was 41 months: beva… (full text at CIViC)

PMID 24703319 · Pentheroudakis et al., 2014 · Open in CIViC

45 Lebanese patients with a reported family history of breast cancer were observed in this study. Using Whole Exome Sequencing (WES) with Sanger sequencing, various germline mutations were found. One … (full text at CIViC)

PMID 28202063 · Jalkh et al., 2017 · Open in CIViC

In this study, the sensitivity to Cisplatin (a platinum-based drug) was studied in XRCC3 knockout, and ORC1 mutant PDX models. A role of XRCC3 loss in cisplatin sensitivity was reported in the study. … (full text at CIViC)

PMID 37029129 · Ter Brugge et al., 2023 · Open in CIViC

ZNF217 overexpression is linked to reduced survival across multiple breast cancer subtypes. A meta-analysis of relapse-free survival across nine studies involving 858 patients revealed that higher ZNF… (full text at CIViC)

PMID 22728437 · Littlepage et al., 2012 · Open in CIViC

Triciribine inhibits ZNF217-driven tumour growth and signalling both in vivo and in vitro. In mouse models, triciribine reduced tumour burden and levels of phospho-AKT and phospho-MAPK, while increasi… (full text at CIViC)

PMID 22728437 · Littlepage et al., 2012 · Open in CIViC